Introduction
============

Steroid hormone receptors are generally intracellular receptors and initiate signal transduction for steroid which lead to changes in gene expression over a time period ranging from hours to days \[[@B1-molecules-15-01161]\]. During the translation, steroid receptors are assembled into a multi-protein complex containing hsp90 (one of the most abundant proteins expressed in cells) \[[@B2-molecules-15-01161]\], p23, an immunophilin, and often some hsp70 \[[@B3-molecules-15-01161]\]. Geldanamycin analogues were found to bind to hsp90 and disrupt its function, impedes dexamethasone-dependent trafficking of the glucocorticoid receptor from the cytoplasm to the nucleus, led many of them are protooncogenic and play a prominent role in cancer \[[@B4-molecules-15-01161]\]. For example, geldanamycin and its analog 17-AAG showed significant cytotoxicity against human cancer cell line SKBr3 (IC~50~ = 41 and 33 nM, respectively) \[[@B5-molecules-15-01161]\]. During our continued work on bioactive bacteria and fungi, a *Streptomyces hygroscopicus* strain was isolated from the soil of Chang-Bai Mountain. A new geldanamycin analogue was isolated from a 20 L fermentation of this strain. Its structure was elucidated as 11-methoxy-17-formyl-17-demethoxy-18-*O*-21-*O*-dihydrogeldanamycin (**1**, [Figure 1](#molecules-15-01161-f001){ref-type="fig"}) on the basis of extensive 1D and 2D NMR as well as HRESI-MS spectroscopic data analysis. Compound **1**was tested with five-day *in vitro* SRB cytotoxicity against human tumors cell lines and showed considerable cytotoxicity against human cancer cell lines (breast cancer MCF-7, skin melanoma SK-MEL-2 and lung carcinoma COR-L23).

![Structure of 11-methoxy-17-formyl-17-demethoxy-18-*O*-21-*O*-dihydrogeldanamycin (**1**).](molecules-15-01161-g001){#molecules-15-01161-f001}

Results and Discussion
======================

Characterization of compound ***1***
------------------------------------

The molecular formula of compound **1** was determined as C~30~H~42~N~2~O~9~ on the basis of its HR-ESI-MS (*m/z* 575.2981 \[M+H\]^+^, calcd. 575.2969) and NMR data ([Table 1](#molecules-15-01161-t001){ref-type="table"}). Analysis of the ^13^C-NMR spectrum and DEPT experiments, allowed the identification of seven methyl groups, two methylenes, eleven methines and ten quaternary carbons. Analysis of the ^1^H-^1^H COSY ([Figure 2](#molecules-15-01161-f002){ref-type="fig"}) and HMQC spectra suggested the presence of two ^1^H-^1^H spin systems: H~3~-H~4~- H~5~-H~6~-H~7~, H~9~-H~10~-H~11~-H~12~-H~13~-H~14~-H~15~. The chemical shifts of the protons and carbons ([Table 1](#molecules-15-01161-t001){ref-type="table"}) were similar to those of the previously reported compound, 17-formyl-17-demethoxy-18-*O*-21-*O*-dihydrogeldanamycin, a geldanamycin analogue isolated from recombinant *S. hygroscopicus* strain \[[@B6-molecules-15-01161]\]. The main differences between the two metabolites concerned a newly appeared methoxyl group \[δ~C~ 57.2, δ~H~ 3.37 (*s*)\] in compound **1**. The location of the methoxyl group was established taking into account the correlation observed between 11-OCH~3~ (δ 3.37) and C-11 (δ 156.8) in the HMBC experiment of **1** ([Figure 2](#molecules-15-01161-f002){ref-type="fig"}). The coupling constant between the H5 and H6 (11.2 Hz), H9 and H10 (8.8 Hz), were similar to the literature values 10.4 Hz and 9.6 Hz \[[@B6-molecules-15-01161]\], respectively, led to determine the relative stereochemistry same as reported compound KOSN 1645.

molecules-15-01161-t001_Table 1

###### 

The NMR data of compound **1**.^a^

  No.           Compound 1               KOSN 1645 ^b^                                    
  ------------- ------------------------ --------------- ------- ------------------------ -------
  1             \-                       169.1           C       \-                       167.3
  2             \-                       135.2           C       \-                       136.7
  3             7.01 (*d*, *J* = 12.0)   124.3           CH      6.85 (*d*, *J* = 11.2)   124.7
  4             6.22 (*t*, *J* = 12.0)   128.6           CH      6.35 (*t*, *J* = 11.2)   127.1
  5             5.24 (*t*, *J* = 11.2)   133.3           CH      5.71 (*t*, *J* = 10.4)   132.9
  6             3.99 (*d*, *J* = 11.2)   79.6            CH      4.31 (*d*, *J* = 10.4)   80.9
  7             4.83 (*s*)               80.7            CH      4.96 (*s*)               82.8
  8             \-                       132.6           C       \-                       133.4
  9             5.47 (*d*, *J* = 8.8)    133.1           CH      5.94 (*d*, *J* = 9.6)    133.4
  10            2.51 (*m*)               32.1            C       2.81 (*qn*, *J* = 7.6)   32.3
  11            3.73 (*m*)               72.9            CH      3.63 (*m*)               74.7
  12            3.57 (*m*)               79.3            CH      3.5 (*m*)                80.3
  13            1.86 (*m*)               33.7            CH~2~   1.88 (*br*)              35.4
  14            1.83 (*m*)               29.3            CH      1.6-1.8 (*ov*)           29.2
  15            2.58 (*m*)               33.1            CH~2~   2.72 (*br*)              33.4
  16            \-                       126.9           C       \-                       127.3
  17            \-                       114.2           C       \-                       113.1
  18            \-                       159.3           C       \-                       159.4
  19            7.71 (*s*)               105.6           CH      7.93 (*s*)               104.7
  20            \-                       132.3           C       \-                       135.6
  21            \-                       140.6           C       \-                       136.4
  2-Me          1.65 (*s*)               11.8            CH~3~   1.59 (*s*)               12.4
  8-Me          1.68 (*s*)               11.3            CH~3~   1.79 (*s*)               12.6
  10-Me         0.91 (*d*, *J* = 7.2)    10.9            CH~3~   0.93 (*d*, *J* = 7.2)    12.1
  14-Me         0.97 (*d*, *J* = 8.8)    23.1            CH~3~   0.95 (*d*, *J* = 8.8)    22.4
  6-OMe         3.29 (*s*)               55.9            CH~3~   3.36 (*s*)               56.9
  11-OMe        3.37 (*s*)               57.2            CH~3~   \-                       \-
  12-OMe        3.31 (*s*)               57.7            CH~3~   3.22 (*d*)               57.1
  17-CHO        9.81 (*s*)               191.0           C       10.09 (*s*)              193.2
  7-carbamate   8.50 (*s*)               155.5           C       8.73 (*s*)               156.5

^a^ Compound **1**was measured in DMSO-*d*6 and chemical shifts are expressed in ppm; ^b1^H and ^13^C-NMR.

![COSY and HMBC of compound **1**.](molecules-15-01161-g002){#molecules-15-01161-f002}

data (in CDCl~3~) of KOSN 1645 were extracted from \[[@B6-molecules-15-01161]\].

The biosyntheses of geldanamycin analogues were reported to be involved in the assembly of 3-amino-5-hydroxybenzoic acid (AHBA) as a starter unit, following elongation with the acyl-Coenzyme A substrates malonyl-CoA, methylmalonyl-CoA, and 2-methoxymalonyl-ACP, the polyketide intermediate undergoes intra-molecular lactamization by gdmF to form progeldanamycin \[[@B5-molecules-15-01161],[@B7-molecules-15-01161]\] ([Figure 3](#molecules-15-01161-f003){ref-type="fig"}). The compound **1** isolated in this study and previously reported herbimycin A \[[@B6-molecules-15-01161]\], proposed that an *O*-methylation step exist after the formation of polyketide backbone which may lead to identify a new *O*-methyltransferase. To prove this hypothesis, mutant lines could be established for screening of this 11-*O*-methyltransferase.

![Speculated biosynthetic pathway of compound **1**.](molecules-15-01161-g003){#molecules-15-01161-f003}

Bioactivity results
-------------------

Compound **1** was tested in anti-tumor bioassays and showed significant cytotoxicity (SRB) against several human cancer cell lines: breast cancer MCF-7 (IC~50~ = 142 nM), skin melanoma SK-MEL-2 (IC~50~ = 496 nM) and lung carcinoma COR-L23 (IC~50~ = 278 nM).

Conclusions
===========

In summary, we have isolated a new geldanamycin analogue 11-methoxy-17-formyl-17-demethoxy-18-*O*-21-*O*-dihydrogeldanamycin (1) from a 20 L of *Streptomyces hygroscopicus* A070101 fermentation broth. Compound 1 showed considerable cytotoxicity against human cancer cell lines (breast cancer MCF-7, skin melanoma SK-MEL-2 and lung carcinoma COR-L23).

Experimental
============

General
-------

The ^1^H- and ^13^C-NMR spectra were measured on a Bruker Avance DRX 500 NMR spectrometer in DMSO-*d*~6~, using TMS as an internal standard. Chemical shifts (*δ*) are expressed in parts per million (ppm), with the coupling constants (*J*) reported in Hertz (Hz). The HR-ESI mass spectrum was obtained from a MDS SCIEX API QSTAR-MS instrument. TLC was performed with silica gel plates (Macherey -Nagel, SilG / UV254, 0.20mm); Semi-preparative HPLC was carried out with Agilent 1100 on a Zorbax C~18~ column (250 x 10 mm, Phenomenex, Torrance, CA), UV absorption data (λ~280~) were analyzed with Agilent Chemstation Ver 8.01. All solvents used in this study were HPLC grade, purchased from the Chinese Chemical Group, Beijing, China.

Bacterial strain and growth conditions
--------------------------------------

Bacterial strain A070101 was obtained from Chang-Bai Mountain soil during a systematic screening of ginsenoside-glucosidase-produced bacteria \[[@B10-molecules-15-01161]\] and was identified as *Streptomyces hygroscopicus* by professor Zhao-Yang He (Jilin Agricultural University). Geldanamycin production medium (GPM), consist of sucrose (50 g/liter), peptone (2 g/liter), tryptone (2 g/liter), yeast-extract (2 g/liter), Gerber\'s oatmeal (5 g/liter), and Brer Rabbit molasses (10 ml/liter) (pH = 7.0), was used to produce geldanamycin homologues \[[@B11-molecules-15-01161]\]. The fermentation was carried in fifty 1 L flasks at 28 °C for 7 days.

Extraction and isolation of compound ***1***
--------------------------------------------

The lyophilized culture broth was extracted with 80% EtOH at room temperature. The extract was concentrated under reduced pressure to give the pale brown residue (625 mg) that was fractionated by reverse phase (C-8) chromatography using H~2~O, aqueous MeOH (30%, 60%, 90%) and MeOH to give four fractions: the 90% MeOH fraction was further fractionated on a Sephadex LH- 20 column (CHCl~3~: MeOH=1:1) and then purify by semi-preparative HPLC to yield compound **1** (3.6 mg, 0.18 mg/L, whereas yield of geldanamycin was reported as \~10 mg/liter) \[[@B6-molecules-15-01161]\].

In vitro cytotoxicity assays
----------------------------

Five-day *in vitro* SRB cytotoxicity tests against human tumors cell lines were carried out at the Cell Culture Laboratory, Pharmaceutical College, Jilin University, using modified protocols for MCF-7 (breast cancer), SK-MEL-2 (skin melanoma) and COR-L23 (lung carcinoma), the normal cells were used as control \[[@B12-molecules-15-01161]\]. Generally, 5x10^3^/mL cells were placed in a 24-well plate and treated with compound **1**. The plate was incubated at 37 °C for 5 days. Then the medium was removed from the 24-well plate, and 10% ice-cold TCA (trichloroacetic acid, 1 mL) was added. The plate was kept at 4 °C for two hours after which was washed four times with cold water, then stained with SRB (Sulforhodamine B, Sigma St. Louis, MO, USA). After washing with 1% acetic acid, the bound dye was solubilized with Tris base A (Sigma) and 100 μL of each sample were transferred into a 96-well plate, and then read at 492 nm.
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